Briacell Therapeutics Corp.
13F holders, Q2 2025 (June 30)16holders +2
4new positions
2sold out
$2.92avg. 13F price*
At the end of Q2 2025, 16 institutions reported holding Briacell Therapeutics Corp. in their 13F filings, up 2 from Q1 2025. 4 opened new positions and 2 sold out. The largest holders were Sabby Management, LLC ($116K), UBS Group AG ($45K) and Federation des caisses Desjardins du Quebec ($10K).
- Company
- Briacell Therapeutics Corp.
- CUSIP
- 107930208
- Latest filing quarter
- Q3 2025
History
Number of 13F holders
Total Exit/New Position Q1 2025 → Q2 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 4 | $127K |
| Exits | 2 | $1K |
All 13F filers, Q1 2025 → Q2 2025: 43,271 shares bought and 7,363 shares sold, net +35,908 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 16 holders
| Sabby Management, LLC | 0.94% | New | 39,530 | $116K |
| UBS Group AG | 0.00% | Reduce -20.1% | 15,243 | $45K |
| Federation des caisses Desjardins du Quebec | 0.00% | New | 3,500 | $10K |
| Royal Bank of Canada | 0.00% | Add +6.9% | 1,069 | $3K |
| Group One Trading LLC | 0.00% | Reduce -75.8% | 708 | $2K |
| SBI Securities Co., Ltd. | 0.00% | No change | 600 | $2K |
| National Bank of Canada | 0.00% | Reduce -31.7% | 645 | $1K |
| TD Waterhouse Canada Inc. | 0.00% | No change | 190 | $543 |
| Raymond James Financial Inc. | 0.00% | New | 102 | $300 |
| Allworth Financial LP | 0.00% | New | 70 | $206 |
| HHM Wealth Advisors, LLC | 0.00% | No change | 66 | $195 |
| Osaic Holdings, Inc. | 0.00% | Reduce -1.5% | 66 | $194 |
| Wells Fargo & Company | 0.00% | No change | 32 | $94 |
| Morgan Stanley | 0.00% | Reduce -97.8% | 13 | $38 |
| BlackRock, Inc. | 0.00% | No change | 1 | $3 |
| FNY Investment Advisers, LLC | 0.00% | Reduce -50.0% | 100 | $0 |
"% of holder's portfolio" is BRIACELL THERAPEUTICS CORP's weight in each manager's 13F, not the share of Briacell Therapeutics Corp. the manager owns.